-
Mashup Score: 0Sotorasib Plus Panitumumab Receives FDA Approval for KRAS G12C–Mutated Colorectal Cancer - 4 hour(s) ago
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) whose disease progressed after chemotherapy.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING 🚨: The FDA approves acalabrutinib plus bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous HSCT. https://t.co/p5Tmrqa3NY
-
-
Mashup Score: 0MaaT013 Achieves Primary Endpoint in ARES Trial for GI-aGVHD - 12 hour(s) ago
MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The phase 3 ARES study shows positive results for MaaT013, meeting its primary endpoint of GI overall response rate at day 28 in patients with steroid- or ruxolitinib-refractory gastrointestinal acute graft-vs-host disease. Read here: https://t.co/XH7t5kBigs
-
-
Mashup Score: 3
GSK5764227 has been granted FDA breakthrough therapy designation, potentially expediting its development as a treatment for relapsed/refractory osteosarcoma.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has designated GSK'227 a breakthrough therapy for the treatment of adult patients with relapsed or refractory osteosarcoma who have received at least 2 prior lines of therapy. Learn more at: https://t.co/QhTQa3XLG9 https://t.co/3V2pe55LsL
-
-
Mashup Score: 2
Frontline treatment with belzutifan and cabozantinib resulted in durable responses and a manageable safety profile in patients with previously untreated advanced ccRCC.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
Frontline therapy with belzutifan in combination with cabozantinib demonstrated durable clinical responses and an acceptable safety profile in patients with treatment-naïve advanced clear cell renal cell carcinoma. Read here: https://t.co/fjqKPp7qEl
-
-
Mashup Score: 0FDA Issues Draft Guidance for Tissue Biopsies in Trials - 4 day(s) ago
The FDA has released draft guidance with recommendations on tissue biopsies in clinical trials for adults and children.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA and Office for Human Research Protections has released draft guidance with recommendations on tissue biopsies in clinical trials for adults and children. Learn more at https://t.co/z4MYkLkbvW
-
-
Mashup Score: 1FDA Grants Priority Review to Sunvozertinib for NSCLC With EGFR Exon 20 Insertion Mutations - 6 day(s) ago
Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted priority review for sunvozertinib to treat patients with platinum-pretreated, locally advanced, or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations detected by an FDA-approved test. Read here: https://t.co/JwQ9qlBAyd
-
-
Mashup Score: 0FDA Fast Tracks Invikafusp Alfa for TMB-High CRC - 7 day(s) ago
Phase 1 data indicate invikafusp alfa’s potential as a precision cancer immunotherapeutic in solid tumors that have progressed after PD-(L)1 therapy.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted fast track designation to invikafusp alfa, a first-in-class selective dual T-cell agonist, for treating patients with unresectable, locally advanced, or metastatic colorectal cancer with high tumor mutational burden. Read more: https://t.co/Rj0P349srI
-
-
Mashup Score: 1
Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The phase 3 MARIPOSA trial revealed that Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant non-small cell lung cancer. Read here: https://t.co/8qlWE5BekG https://t.co/7XGG125HJy
-
-
Mashup Score: 1
Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The phase 3 MARIPOSA trial revealed that Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant non-small cell lung cancer. Read here: https://t.co/8qlWE5BekG https://t.co/7XGG125HJy
-
BREAKING 📰: The FDA approved sotorasib with panitumumab as a treatment for patients with KRAS G12C-mutated metastatic colorectal cancer whose disease progressed after chemotherapy. https://t.co/692sTTvovQ